RecruitingNCT05068531

Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients

A Prospective Observational Cohort Study for Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients Undergoing Systemic Chemotherapy and Liver Resection With Curative Intent

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

100 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Colorectal Cancer Metastatic

Summary

In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy. Actuarial data however supports that approximately 20% of mCRC-LR patients can be cured without as much systemic chemotherapy. Prospective phase II-III trials also support that awaiting recurrence to initiate further metastases-targeted or systemic treatment may provide patients with longer overall survival while avoiding toxicities in those without recurrence.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study follows patients with colorectal cancer that has spread only to the liver and are scheduled for liver surgery to remove the tumors with curative intent. Researchers use blood-based liquid biopsy tests to see if they can detect early signs of treatment failure before it shows up on scans. **You may be eligible if...** - You are 18 or older with stage IV colon or rectal cancer that has spread only to the liver - You are scheduled for liver surgery (partial hepatectomy) or liver ablation (radiofrequency/microwave) with curative intent - You are willing to provide serial blood, tissue, and stool samples for research **You may NOT be eligible if...** - Your cancer has spread beyond the liver (confirmed extra-hepatic metastases) - You are unwilling to provide research samples Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.